In the world of cancer treatment, innovation is a lifeline for millions battling the disease. Nowhere is this more evident than in proton therapy, where continuous advancements are critical to bring the treatment to more patients that need it. Mevion is at the forefront of this evolution, a company that was born from the collaborative efforts with the Massachusetts Institute of Technology (MIT). At the 2024 National Proton Conference, Mevion shared its inspiring history and forward-thinking vision to re-imagine proton therapy.

On April 6th, 2024, Mevion welcomed attendees of the National Proton Conference to its Littleton,

MA headquarters, offering a glimpse into its two-decade journey of innovation. The tour featured

six insightful presentations from key departments, showcasing Mevion's commitment to advancing proton therapy.

Unveiling the Never-Before-Seen MEVION S250-FIT

Unveiling the Never-Before-Seen MEVION S250-FIT

The highlight of the tour was the first-ever public viewing of the MEVION S250-FIT*. Adam Molzahn (Head of Global Systems Architecture) and Dr. Rocky Owen (Clinical R&D Engineer and Relationship Manager) showcased the FIT vault and treatment room, where cutting-edge technology meets patient-centric design. The FIT system aims to democratize proton therapy by significantly reducing its size and cost.

Key Features of the FIT System:

• HYPERSCAN IMPT with pMLC
• Upright patient positioning (Leo Cancer Care)
• CT imaging for IGRT and adaptive treatment

World's smallest proton therapy accelerator

Mevion's Chief Technology Officer, Mark Jones, leads the development of the world's smallest proton therapy accelerator, leveraging the power of superconducting materials. By utilizing zero-resistance conductors, the team has achieved compact accelerators with enhanced amp capacity and efficiency. Through meticulous quality inspection and close collaboration with magnet manufacturers, Mevion has manufactured many accelerators and each of them has been named after industry luminaries or key employees symbolizing their profound significance and complexity.

Accelerating progress

Dr. Townsend Zwart, Vice President of Advanced Development, explained how the superconducting proton accelerator is at the heart of Mevion's innovation. The ability to generate a 10-tesla field within a 30 cm radius and propel beams near two-thirds the speed of light allows systems like the MEVION S250i and S250-FIT* to offer compact, efficient proton therapy. Their adaptability extends to diverse clinical and research environments, making waves in flash radiotherapy research and fitting seamlessly into existing infrastructures like the LINAC vaults at Stanford Health.

precision in motion

Katelyn Milkowski, Head of Engineering for the S250-Series, detailed the beam line's design, emphasizing precision and efficiency. Features like ultra-fast proton energy switching, adaptive aperture, and volumetric repainting ensure optimal treatment delivery.

FIT for success

Jeff Anderson, Director of Site Design and Construction presented how the MEVION S250-FIT* is specifically designed for ease of clinical integration. Its simplified electrical system and compact cooling solution reduce installation complexity and space requirements, while enhancing system performance. The streamlined design of the FIT system supports fast integration in diverse clinical settings, including in existing LINAC vaults.

upright patient positioning

Lydia Ooyama (Senior Product Manager) and Shane Ikner (Training Manager from Leo Cancer Care) demonstrated the simulation room, where the Leo Cancer Care Upright patient positioning system optimizes patient alignment and comfort, improving treatment accuracy. Dr. Niek Schreuder, Chief Scientific Officer at Leo Cancer Care, provided a comprehensive overview of upright positioning, emphasizing its benefits for both adult and pediatric patients.

advancing technology

RaySearch Laboratories showcased the impressive capabilities of Mevion's HYPERSCAN pencil beam scanning system at the event. Their powerful RayStation software drives the system, allowing for exceptional multi-layer treatment planning and precision radiation therapy. Attendees witnessed how the HYPERSCAN advanced proton MLC, with its fast energy switching, can significantly enhance treatment plans for even the most complex cancer cases. This collaboration underscores the dedication of both RaySearch and Mevion to drive innovation and provide cutting-edge tools for improved patient care.

mevion's journey and the future of proton therapy

Mevion's advancements in superconducting proton therapy represent a remarkable story of innovation and dedication. As technology evolves, so does the hope for a future where cancer is conquered with precision, efficiency, and compassion.

*The MEVION S250-FIT Proton Therapy System is not yet available for clinical use.